CYP3A4 and COVID-19: Our findings bring novel evidence of NR3C1 rs6198, GSTP1 rs1695, and CYP3A4 rs35599367 polymorphisms having impact on COVID-19 severity, the course of the disease, and the outcome of treatment with dexamethasone and methylprednisolone.